Many individual polycyclic aromatic hydrocarbons (PAH) are genotoxic carcinogens. One of the parent PAH, pyrene, undergoes simple metabolism to 1-hydroxypyrene. 1-Hydroxypyrene and its glucuronide are excreted in urine. Biological monitoring of exposure to PAH has rapidly been expanded since urinary 1-hydroxypyrene was suggested as a biological index of dose of pyrene. Since pyrene is always present in PAH mixtures, the biological indicator is not only an indicator of uptake of pyrene, but also an indirect indicator of all PAH. At present, several hundreds of papers reporting on urinary concentrations of 1-hydroxypyrene in workers' urine are available. It appeared that urinary 1-hydroxypyrene is a sound biomarker and that the analytical method is robust and non-laborious. Since epidemiological studies of cancer mortality related to long-term average urinary 1-hydroxypyrene concentration are lacking, a sound health-based limit value of 1-hydroxypyrene in urine cannot be set as yet. Since PAH exposure is widespread and the dermal uptake is substantial among exposed workers, an attempt was made to propose a three-level benchmark guideline for urinary 1-hydroxypyrene. The reference value as a 95th percentile in non-occupational exposed controls is 0.24 mmol mol ؊1 creatinine and 0.76 mmol mol ؊1 creatinine for non-smokers and smokers, respectively. This is the first level of the benchmark guideline. A no-biological-effect-level of 1-hydroxypyrene in urine of exposed workers was found at 1.4 mmol mol ؊1 creatinine. It is the lowest reported level at which no genotoxic effects were found and therefore the estimate for the second level of the benchmark guideline. In two types of industry, cokeovens and primary aluminium production, the regression of airborne PAH concentrations and urinary 1-hydroxypyrene concentrations in exposed workers has been studied. The correlation of airborne concentrations and urinary 1-hydroxypyrene in urine of workers from cokeovens and in the primary aluminium industry was used to estimate the level of urinary 1-hydroxypyrene equal to the present occupational exposure limit (OEL) of PAH. The concentration of 1-hydroxypyrene in urine equal to the OEL is 2.3 mmol mol ؊1 creatinine and 4.9 mmol mol ؊1 creatinine, respectively, in these two industries. These latter values present the third level of the benchmark guideline.
INTRODUCTION
The most important sources of occupational exposure to polycyclic aromatic hydrocarbons (PAH) are coal tars and derived products. Crude coal tar is a by-product of coke works and was in former times also a by-product of gasworks. Crude coal tar is usually distilled and blends of distillation fractions are used for 4 F. J. Jongeneelen erator fumes, etc. PAH are present in the environment (air, water and soil) as trace contaminants. PAH are mostly non-volatile compounds. Airborne PAH with fewer than four aromatic rings (molecular weight range of 128-178) are merely present as gaseous compounds in the working environment. PAH with four rings (molecular weight of 202) are present both as gaseous compounds and as particulate matter. PAH with larger molecular weights (>228) are merely bound to airborne particulates.
The International Agency for Research on Cancer reported that workers from industrial settings where airborne PAH levels are high, such as gas works, coke works, and the primary aluminium industry, show excess rates of cancers. Aluminium production, coke production, coal gasification and coal tar pitches/coal tar fumes are carcinogenic to humans according to IARC classifications (IARC, 1983 (IARC, , 1984 (IARC, , 1985 . PAH are genotoxic carcinogens, inducing chromosomal effects in exposed individuals. The most toxic effects on humans, other than cancer, arising from PAH-containing coal tars and creosote oils concern the skin and eyes. An overview of effects is given in the ACGIH's TLV documentation of coal tar pitch volatiles and benzo(a)pyrene (ACGIH, 1998) .
Since the 1940s, the exposure of workers to PAH has been assessed by measurements of workroom air. In the 1970s personal air sampling replaced static air sampling. In many studies it has not been the PAH itself, but a surrogate, namely coal tar pitch volatiles (CTPV) as benzene soluble matter (BSM) which has been used as the indicator of airborne PAH. Only in the last decade has the direct determination of 16 EPA-PAH, or a single marker-that is benzo(a)pyrene [b(a)p]-in workroom air been more often chosen as the preferred marker. A recent change in the sampling method of PAH is that not only are the particulates sampled, but also the gaseous fraction of the PAH (Noto et al., 1996) . The OEL for coal tar pitch volatiles of many countries is 0.2 mg m Ϫ3 as benzene soluble matter. Knowing that the US TLV of coal tar pitch volatiles (CTPV) has not been based on risk levels from epidemiological studies, but rather on analytical demands (detectable concentration of benzene solubles), it should be clear that the TLV of CTPV has no solid health-risk basement, but is more or less a practical compromise (ACGIH, 1998) . The German TRK for benzo(a)pyrene is 2 µg m Ϫ3 (exception for cokeoven: 5 µg m Ϫ3 ), which is a reasonably achievable limit. Several industrial processes emitting PAH (cokeoven, aluminium production, coal gasification, iron and steel founding) are classified as Class 1 carcinogens by the IARC (1984) .
Studies of routes of exposure among PAH-exposed workers suggest that the major routes of occupational exposure to pyrene are through inhalation and cutaneous absorption. The dermal exposure of workers is very significant. It was estimated that the uptake of pyrene via the dermal route accounts for 50% of the total body dose for cokeoven workers (Vanrooij et al., 1993a) . This is even as high as 90% for creosoteimpregnating workers (Vanrooij et al., 1993b) . Among coal liquefaction workers the dermal exposure was estimated to account for 70% of the excreted PAH metabolite (Quinlan et al., 1995) . Another report shows that cokeoven workers show a substantial concentration of a PAH metabolite in urine even without detectable PAH in the air (Malkin et al., 1996) . The excretion of 1-hydroxypyrene in urine of volunteers exposed to pyrene by the dermal route was very significant (Viau and Vyskocil, 1995) .
There is a growing awareness that occupational PAH uptake via the skin is very substantial. Recently it became clear that dermal exposure to PAH not only results in local effects on the skin, but results also in systemic effects. PAH-DNA adducts were found in the lungs after dermal application of tar and bitumen products on the skin of mice (Schoket et al., 1988) . Lung cancer risk following skin uptake of PAH can therefore not be ruled out.
The UK ACTS has agreed a framework for the use of biological monitoring guideline values as either health-based guidance values or hygiene-based guidance values, which are set around the 90th percentile of available validated data (HSE, 1996) . Since no epidemiology with any biomarker as a dose indicator of PAH exposure is available, a health-based guideline value cannot be set. However, PAH form a class of genotoxic carcinogenic compounds for which exposure should be maintained at the lowest levels achievable. Therefore an attempt is made in this study to propose a benchmark guideline using the presently available knowledge of background exposure levels and exposure levels without genotoxic effects in PAH-exposed workers.
BIOLOGICAL MONITORING METHODS FOR PAH
Uptake of PAH in the body may be monitored by different biomarkers, for example metabolites in urine, urinary thioethers, urinary mutagenicity, PAHprotein adducts and PAH-DNA adducts. Both urinary mutagenicity and urinary thioethers are non-specific indicators of exposure to mutagenic agents. The latter two methods lack sensitivity in the case of occupational exposure to PAH and smoking is a very strong interfering confounder (Clonfero et al., 1989; Reuterwall et al., 1991; Ferreira et al., 1994a) . These methods are not suitable for routine applications. Haemoglobin adducts of benzo(a)pyrene have been reported as possible biomarkers for exposure. However, there is still little experience and the first results show limited usefulness (Ferreira et al., 1994b) .
A large effort has been made to use the extent to which PAH binds to DNA as a biomarker of exposure. White blood cells are used as surrogate target DNA. Enzyme immunoassays (Santella, 1988 ) and 32 P post-labelling assays (Beach and Gupta, 5 Urinary 1-hydroxypyrene as PAH biomarker 1992) have been suggested. Both methods may be subject to appreciable variation, as was demonstrated in several recent trials Castegnaro, 1993, 1999) . A clear relationship between PAH exposure and PAH-DNA adducts has not yet been established. Moreover, the present post-labelling method is laborious.
A specific metabolite of pyrene, 1-hydroxypyrene, in urine has been suggested as a biomarker of human exposure to PAH (Jongeneelen et al., 1985) . The abundance of the pyrene, a non-carcinogenic PAH, is relatively high in PAH mixtures (Jongeneelen et al., 1985; Buchet et al., 1992) . Many reports from different sources confirmed the potential of the methodology (Jongeneelen et al., 1988 (Jongeneelen et al., , 1990 Clonfero et al., 1989; Tolos et al., 1990; Zhao et al., 1990 Zhao et al., , 1992 Zhao et al., , 1996 Buckley and Lioy, 1992; Burgaz et al., 1992; Gardiner et al., 1992; Sherson et al., 1992; Granella and Clonfero, 1993; Schaller et al., 1993; Tjoe Ny et al., 1993; Boogaard and van Sittert, 1994; Buchet et al., 1995; Levin, 1995; Quinlan et al., 1995; van Schooten et al., 1995; Gundel et al., 1996; Kuljukka et al., 1996 Kuljukka et al., , 1998 Malkin et al., 1996; Strickland et al., 1996; WHO, 1996; Angerer et al., 1997; Mielzynska et al., 1997; Popp et al., 1997; Merlo et al., 1998; Pan et al., 1998; Wu et al., 1998a; Cartensen et al., 1999) . At present, urinary 1-hydroxypyrene is a widely used biological indicator of exposure to PAH; a search of the Toxline bibliographic database in 1999 with the keyword 'hydroxypyrene' resulted in approximately 400 papers reporting on studies of this biomarker. The conclusion of the first international workshop on 1-hydroxypyrene was that the analytical method is robust and that urinary 1-hydroxypyrene is a solid biological exposure indicator (Levin, 1995) .
Recently, the glucuronide of 1-hydroxypyrene has also been used and proposed as an indicator of exposure, since the majority of 1-hydroxypyrene is conjugated and the fluorescence intensity is higher, but it has not yet shown its additional value (Strickland et al., 1996) .
The measurement of various hydroxylated phenanthrenes has also been reported as a biomarker of exposure using GC-MS (Grimmer et al., 1991 (Grimmer et al., , 1993 and HPLC (Popp et al., 1997; Gundel et al., 1996) . However, the experience is still limited and the sample clean-up procedure for the gas chromatographic analysis is more laborious. A recent attempt with immunoaffinity separation of PAH metabolites from urine of exposed workers showed the presence of both 1-hydroxypyrene and several hydroxyphenanthrenes (Bentsen-Farmen et al., 1999) . A recent thorough review of biomarkers of PAH in environmental health suggests that urinary 1-hydroxypyrene as the most relevant parameter for estimating individual exposure to PAH (Dor et al., 1999) .
1-HYDROXYPYRENE IN URINE

Metabolism and kinetics
Pyrene is metabolized into the intermediary 1-hydroxypyrene to form 1-hydroxypyrene-glucuronide, which is excreted (Jongeneelen et al., 1987) . 1,2-Dihydroxy-1,2-dihydropyrene has been reported to be present in human urine as a minor metabolite (Grimmer et al., 1993) . [ 14 C]Pyrene was rapidly distributed, metabolized, and eliminated from the body and 1-hydroxypyrene is a reliable indicator of systemic exposure to this polycyclic aromatic hydrocarbon. 1-Hydroxypyrene in urine indicates a constant fraction of total 14 C in urine and faeces (Bouchard et al., 1998) .
The half-life for the urinary excretion of 1-hydroxypyrene in occupational exposed workers is 18 h (Buchet et al., 1992) . The individual half-life ranges from 6 to 35 h (Jongeneelen et al., 1990) . Boogaard and van Sittert (1994) reported a half-life of 13 (4-27) h in 16 workers. Therefore, urine should preferably be sampled end-of-shift at the end of the working week.
Biological levels without occupational exposure
Populations generally are exposed to traces of environmental PAH. Pathways include inhalation (air, smoking), ingestion (diet, drinking water) and dermal absorption (through medicinal drugs for the skin, children playing on and in dermal contact with contaminated soil). It is estimated that smoking and diet are the most important sources of PAH intake (IARC, 1983) . Inhalation of urban air may be an additional source. Dermal treatment with pharmaceutical products containing low concentrations of tar or creosotes may be a significant source of dermally absorbed PAH. The conclusion of the first international workshop on 1-hydroxypyrene was that the baseline excretion value varies from country to country (Levin, 1995) . Several studies among inhabitants of Europe, America and Asia show an increased level of urinary 1-hydroxypyrene among smokers; in most studies this level is significantly greater when compared with the levels for non-smokers (Table 1) . Vanrooij et al. (1994) studied sources of inter-individual variation of urinary 1-hydroxypyrene. They concluded that smoking and dietary intake of PAH are the major factors contributing to the variation. Intake of polycyclic aromatic hydrocarbons is mainly from ingestion of dietary PAH and through smoking. Gundel et al. (1996) showed that the influence of smoking is of such an order of magnitude that potential environmental exposure to PAH is obscured by smoking. Merlo et al. (1998) studied inter-individual differences in traffic police officers, including gene polymorphisms. The level of urinary 1-hydroxypyrene was clearly associated with cigarette smoking and to a lesser extent with exposure to outdoor PAH pol-6 F. J. Jongeneelen Table 1 . 1-Hydroxypyrene in urine from non-occupationally exposed controls from various countries by smoking habits (Levin, 1995; WHO, 1996) (Tolos et al., 1990) ; (***) range of five controls (Buckley and Lioy, 1992) .
lution. A significant role of the cytochrome P450 1A1 and/or glutathione-S-tranferase M1 was not detected.
Recommended analytical method
The total of free and conjugated 1-hydroxypyrene is preferably determined with high pressure liquid chromatography (HPLC). After enzymatic hydrolysis to release the conjugated part of 1-hydroxypyrene the analyte is separated from the matrix and enriched by reversed phase column extraction. The components of the eluate are separated by HPLC and 1-hydroxypyrene is determined with a fluorescence detector. The results are corrected for urinary creatinine content.
The most comprehensive description of the method is that of Jongeneelen et al. (1987) . Descriptions of other adapted methods include Boos et al. (1992) and Hansen et al. (1993) . Reference to the independent testing of the methodcan be found in Angerer and Schaller (1991) . Detection of 1-hydroxypyrene in urine is a toxicological analysis of biological material for which an European interlaboratory comparison programme has been established (Lehnert et al., 1999) .
Sampling and storage
Urine should preferably be sampled at the end-ofshift on the last day of a routine working week. Sample contamination is not likely since 1-hydroxypyrene is a metabolite formed in the body. Urine can be collected in any clean container. Approximately 25 ml of urine will be sufficient for a duplicate analysis. Urine is collected in a container without preservative. When the samples are stored in the dark at 18°C, the samples can be kept for at least a year without loss of 1-hydroxypyrene (Jongeneelen et al., 1987) .
JUSTIFICATION FOR A BENCHMARK GUIDELINE
Biological monitoring of occupational exposure to PAH has rapidly been expanded since urinary 1-hydroxypyrene was suggested in 1985 as a biological index of exposure to pyrene (Jongeneelen et al., 1985) . Since pyrene is always present in PAH mixtures, the biological indicator is not only an indicator of uptake of pyrene, but also an indirect indicator of all PAH.
The composition of the PAH mixture in different work environments is, however, not fixed, but varies. When a single compound is used as an indicator or marker, one has to realize that the relative proportion of an individual PAH in the PAH mixture can vary from time to time and place to place. Comparative measurements of PAH in airborne particulate matter within a certain worksite have shown that the relative contribution of each PAH (the PAH profile) is relatively constant, but the relative proportion of pyrene in the PAH profiles between different worksites may differ significantly (König et al., 1985; Lesage et al., 1987) . Since the relative proportion of pyrene in the PAH mixture derived from different work environments may vary, a biological exposure limit of 1-hydroxypyrene in urine valid for all industries cannot be set. Moreover, the epidemiological dose-response of urinary 1-hydroxypyrene and mortality is lacking, as with all new exposure indicators.
Polycyclic aromatic hydrocarbons represent a group of compounds with many genotoxic carcinogens; thus exposure should be maintained at as low a level as is reasonably possible. In occupational health practice there is a need for a guideline to interpret the levels of 1-hydroxypyrene in the urine of exposed workers. A benchmark guideline may fill this gap. There are several high-quality studies on exposure to PAH and their genotoxic effects in workers from different industries that can be used for the setting of some yardsticks.
Laboratory studies
In an animal model, the linearity of excretion of 1-hydroxypyrene was confirmed over an oral dose range of pyrene from 0.05 µg per rat to 500 µg per rat (Jongeneelen et al., 1985) . The quantity of 1-hydroxypyrene in rat urine collected in 24 h samples during the 4 days after dosing, was proportional to the dose of pyrene over the whole range. [ 7 Urinary 1-hydroxypyrene as PAH biomarker the body. 1-Hydroxypyrene in urine represented a constant fraction of total 14 C in urine and faeces (Bouchard et al., 1998) .
Baseline levels
It is known that there is a baseline excretion of urinary 1-hydroxypyrene, mainly due to dietary intake of PAH and smoking (Table 1) . With the distribution of urinary 1-hydroxypyrene in groups of referents, percentile values of background levels may be derived. Concentration of 1-hydroxypyrene in urine of male residents of a medium-sized city in The Netherlands (n = 100) expressed as a 95th percentile is 0.66 µmol mol Ϫ1 creatinine for non-smoking referents and 1.31 µmol mol Ϫ1 creatinine for smoking referents (Jongeneelen et al., 1988) . Non-occupationally exposed males in The Netherlands ( n = 76) had a 95th percentile of 0.29 µmol mol Ϫ1 creatinine and 0.79 µmol mol Ϫ1 creatinine for non-smokers and smokers, respectively (Vanrooij et al., 1994) . Concentration of 1-hydroxypyrene in urine of female residents of an industrial area in Germany (n = 124), expressed as 95th percentiles, is 0.24 µmol mol Ϫ1 creatinine for non-smoking referents and 0.76 µmol mol Ϫ1 creatinine for smoking referents (Gundel et al., 1996) . Zhao et al. (1996, abstract) estimated the limit levels of environmental PAH pollution. They proposed that 0.70 µg per 100 m 3 of benzo(a)pyrene for outdoor urban air and 0.34 µg l.
Ϫ1 of 1-hydroxypyrene in urine (equal to Ϸ0.70 µmol mol
Ϫ1
) is the negligible risk level of urban residents in China.
The lowest reported 95th percentiles of non-occupational exposed individuals have been used to propose the first level of the benchmark guideline for 1-hydroxypyrene in urine; this first level is, for nonsmokers, 0.24 µmol mol Ϫ1 creatinine and for smokers, 0.76 µmol mol Ϫ1 creatinine.
Field studies of the relation between urinary 1-hydroxypyrene and genotoxic effects in exposed workers
Three studies are available of genotoxic events in workers exposed to PAH which could be correlated to the level of urinary 1-hydroxypyrene.
1. Buchet et al. (1995) measured cytogenetic endpoints in lymphocytes, several tumour markers in serum and modified nucleosides in 149 workers. The Belgian workers were from cokeovens, rolling mills and from a graphite anode production plant, and were all heavily exposed to PAH with known levels of post-shift urinary 1-hydroxypyrene. The levels of the genotoxic effects were compared with the data of 137 controls. It appeared that sister chromatid exchanges and high-frequency cells (HFC-SCEs) in lymphocytes were the earliest biological effects and were consistently associated with the intensity of the current exposure to PAH. The level for urinary 1-hydroxypyrene in postshift samples corresponding to 10% probability of increased HFC-SCEs was 6.0 µg g Ϫ1 ( 3.1 µmol mol Ϫ1 ) for the non-smokers and 0.6 µg g Ϫ1 (0.3 µmol mol Ϫ1 ) for the smokers. It was found that in the non-smoking workers an increased level of HFC-SCEs was not observed below the level of 2.7 µg g Ϫ1 (1.4 µmol mol
Ϫ1
. This level is the no-observed-effect-level of this study. 2. German cokeoven workers (n = 29) exposed to an average benzo(a)pyrene concentration of 1.7 µg m Ϫ3 were studied for genotoxic effects (DNA single-strand breakage, DNA adducts and SCEs in lymphocytes). The cokeoven workers had significantly increased DNA-strand breaks in lymphocytes compared with standardized controls ( n = 24). The workers had a mean 24 h excretion in urine of 3.6 µg 1-hydroxypyrene (47). A value of 3.6 µg 1-hydroxypyrene per 24 h urine equals on average 3.6 µg g Ϫ1 creatinine representing 1.9 µmol mol Ϫ1 . This level is the lowest-observedlevel of genotoxic effects in this study (Popp et al., 1997) . 3. Van Schooten et al. (1995) determined PAH-DNA adducts in lymphocytes of 57 exposed workers of a primary aluminium plant. The average adduct level of the high exposed group (number of workers equal to 29 from the bakeoven, anode factory and pot-relining departments) were significantly increased compared with a group of 14 controls. The average post-shift urinary 1-hydroxypyrene level of this high exposed group was 3.8 µmol mol Ϫ1 for non-smokers and 7.2 µmol mol Ϫ1 for smokers. The level of 3.8 µmol mol
is the lowest-observed-level of a specific genotoxic effect. Table 2 summarizes the data of the three studies. There is also a number of studies of PAH-DNA adducts in aluminium and electrode paste plant workers that are negative (Cartensen et al., 1999) . The study of Buchet et al. (1995) showed a no-observedeffect-level in non-smoking workers of genotoxic effect markers at a level of 1.4 µmol mol Ϫ1 creatinine. It seems to be the lowest exposure level in PAHexposed cokeoven plus graphite anode workers without genotoxic effects. This level is proposed as the second level of the benchmark guideline.
Field studies of the relation between personal airborne PAH and urinary 1-hydroxypyrene in exposed workers
Further, a third level of the benchmark guideline can be proposed, based on studies with air concentrations of PAH and urinary 1-hydroxypyrene. Individual authors have reported on the relation of airborne PAH and 1-hydroxypyrene in urine among workers. The airborne occupational exposure limit (OEL) of PAH is expressed as BSM equal to 0.2 mg m Ϫ3 (TLV from USA) or as benzo(a)pyrene equal to 2 µg m Ϫ3 (TRK from Germany). Four studies are available in which a recommendation for a urinary limit value equal to the present available OEL is made, and four studies present data to derive a limit value. These studies are described below.
1. Jongeneelen et al. (1990 Jongeneelen et al. ( , 1992 )studied the PAH exposure of 56 cokeoven workers from The Netherlands. They did personal 8 h air sampling and at the end of the working week urine samples were collected. Total PAH and benzene soluble matter (BSM) were determined in the air samples. Urine samples were tested for 1-hydroxypyrene. A regression line of the concentration BSM in the air and end-of-week urinary 1-hydroxypyrene was calculated in order to find the concentration of 1-hydroxypyrene equalling the TWA-TLV of 0.2 mg m Ϫ3 BSM. Doing this they proposed an end-of-working-week biological exposure limit of 2.3 µmol mol Ϫ1 . 2. Vanrooij et al. (1993a) followed 12 cokeoven workers of a second Dutch cokeoven during a working period of five shifts. During every shift 8 h personal air sampling of PAH was done and end-of-shift urine samples were collected. A regression equation of the five-shift average concentration of benzo(a)pyrene in the air and endof-week urinary 1-hydroxypyrene was calculated. These authors proposed a limit of 3.2 µmol mol
Ϫ1
(end of working week) as equal to an airborne concentration of 2 µg m Ϫ3 benzo(a)pyrene (equivalent to the German TRK value). 3. Kuljukka et al. (1996) studied the exposure of 49
Estonian cokery workers to PAH at a shale oil processing plant. Two personal 8 h air samples of PAH and two urine samples at the end of shift for each worker were collected. Totals of PAH were determined in the air samples. Urine samples were tested for 1-hydroxypyrene. A regression equation of the concentration of benzo(a)pyrene in air and the increase of urinary 1-hydroxypyrene over the working week was derived from the data of the authors, after supplying additional data (personal communication). The data showed that at an airborne concentration of 2 µg m Ϫ3 b(a)p (equivalent to the German TRK value) equals an end-of-shift urinary 1-hydroxypyrene level of 3.0 µmol mol Ϫ1 . The mean PAH-DNA adduct level in white blood cells (WBC) of these cokeoven workers was not significantly increased, compared with controls (Kuljukka et al., 1998) . 4. In a group of 24 Polish cokeoven workers, the median airborne b(a)p concentration varied by 2.1 µg m Ϫ3 and the median concentration of 1-hydroxypyrene in end-of-shift samples was 2.26 µmol mol
Ϫ1 . An estimation of a limit value was not made by the authors, probably because of the low correlation of b(a)p in air and 1-hydroxypyrene in urine (r = 0.26) (Mielzynska et al., 1997 ). An explanation might be that the existing dermal exposure varies strongly between workers. On average it seems that at an airborne concentration of 2 µg m Ϫ3 b(a)p (equivalent to the German TRK value) in this study represents an end-of-shift urinary 1-hydroxypyrene level of 2.3 µmol mol Ϫ1 . 5. Wu et al. (1998a) as the TLV-equal urinary concentration, expressed as a maximal weekly increase. The mean preworking week concentration of 1-hydroxypyrene was 0.6 µmol mol Ϫ1 . The TLV-equal concentration of 1-hydroxypyrene for workers in primary aluminium production, expressed as an end-ofshift limit value, is 4.3 + 0.6 = 4.9 µmol mol Ϫ1 . 8. Angerer et al. (1997) reported industrial hygiene measurement of PAH among 67 workers in a graphite electrode producing plant in Germany. A personal 8 h air sample of PAH and one urine sample after the working shift of each worker were collected. Benzo(a)pyrene was determined in the air samples. Urine samples were tested for 1-hydroxypyrene. A regression equation of the concentration of benzo(a)pyrene in the air and 1-hydroxypyrene in post-shift urine was calculated in order to find the concentration of 1-hydroxypyrenene equalling the German limit value (TRK) of 2 µg m Ϫ3 benzo(a)pyrene. They suggested 40 µg g Ϫ1 creatinine (95%CI range of 20-74). This is equal to 21 µmol mol Ϫ1 creatinine.
The data are summarized in Table 3 . The data were obtained from two types of industry. Since it is known that the PAH profile can vary substantially in different worksites and industries, a third level of the benchmark guideline was suggested for each of the two types of industry:
ț Cokeoven: an end-of-working week value of 2.3 µmol mol Ϫ1 creatinine is the lowest reported estimate for the concentration equal to the OEL. This concentration of 2.3 µmol mol Ϫ1 creatinine is proposed as the best available estimate for the third level of the benchmark guideline, solely valid for cokeoven workers. ț Primary aluminium industry: an end-of-working week value of 4.9 µmol mol Ϫ1 creatinine is the lowest estimate for the concentration equal to the OEL from two studies. It is known that the relative proportion of pyrene in the PAH mixture is not constant; the CTPV of the primary aluminium industry contains relatively more pyrene than the CTPV of cokeovens. The urine concentration in primary aluminium workers will therefore be somewhat higher when reaching the CTPV limit value. The concentration of 4.9 µmol mol Ϫ1 creatinine is proposed as the best available estimate of the third level of a benchmark guideline, solely valid for workers involved in primary aluminium production and graphite electrode production. DISCUSSION PAH-exposed workers undergo inhalation exposure, dermal exposure and oral exposure to a certain extent. Any exposure to genotoxic carcinogens as represented by PAH mixtures is assumed to pose a certain excess risk of cancer.
The concentration of 1-hydroxypyrene in urine, collected at the end of a working week, can be used as a biological indicator of recent doses of PAH. The presence of 1-hydroxypyrene in the urine represents the sum of resorption in the airways, resorption in the gastro-intestinal tract due to the swallowing of coarse particles and via the dermal route. The urine test is specific for exposure to pyrene, which is always present in mixtures of PAH. At present, 1-hydroxypyrene in urine is often used as a biomarker of the dosage of PAH. Pyrene itself is not genotoxic, but the PAH mixture contains many other genotoxic PAH.
The relative proportion of pyrene in the PAH mixtures from different industries or worksites may vary. This implies that the ratio of pyrene to carcinogenic PAH also varies. This factor is an important confounder of the dose-response relationship of the long-term average of urinary 1-hydroxypyrene versus excess cancer in exposed workers. The variation of the pyrene content in the total PAH for the various work environments makes obligatory the analysis of the abundance of pyrene in the PAH mixture at each site where workers are being monitored for urinary 1-hydroxypyrene.
No epidemiology of the long-term average of urinary 1-hydroxypyrene versus cancer outcome is available as yet. A sound health-based limit value, valid for all types of industries, cannot be recommended at present. An approach based on benchmark guidelines is the best feasible alternative for the moment. Three Table 3 . Studies of personal air sampling of PAH and 1-hydroxypyrene in urine of workers used for an estimation of the urinary metabolite level equal to the airborne occupational exposure limit of PAH levels are proposed. The first level of the benchmark guideline is derived from the consideration that PAH mixtures are carcinogenic to humans, acting via a genotoxic mechanism. Exposure to the PAH mixture should be modified to the lowest feasible level. There is a baseline excretion of urinary 1-hydroxypyrene in referents, mainly due to dietary intake of PAH and smoking. The 95th percentile of referents are 0.24 µmol mol Ϫ1 creatinine for non-smokers and 0.76 µmol mol Ϫ1 creatinine for smokers. This is proposed as the first level of the benchmark guideline.
The second level is the prevention of genotoxic events such as DNA adducts and chromosomal effects in exposed workers. The long-term significance of these genotoxic effects is still unknown. For preventive action it seems to justified to maintain the exposure at a level which prevents an increased prevalence of genotoxic effects. The no-observedeffect-level of genotoxic effects in workers is found at a concentration level for 1-hydroxypyrene of 1.4 µmol mol Ϫ1 creatinine. A third level of the benchmark guideline can be set at the level of the present OELs for PAH. However, the relative proportion of pyrene in the PAH mixture derived from different industries or worksites is not constant and this confounds the relationship between airborne PAH and urinary 1-hydroxypyrene in exposed workers. It seems that the PAH mixture is constant within a certain type of industry; therefore an industry-specific benchmark guideline is proposed. For cokeovens and primary aluminium production several studies are available in which the concentration for airborne PAH is related to urinary 1-hydroxypyrene. The OEL equal levels of urinary 1-hydroxypyrene in cokeoven workers show a wide range; the concentrations range from 2.3 to 25.0 µmol mol Ϫ1 creatinine as equal to the US TLV of 0.2 mg m Ϫ3 as BSM or equal to the German TRK of 2 µg m Ϫ3 benzo(a)pyrene. It might be that the higher dermal exposure level at some cokeovens is responsible for the higher level of urinary 1-hydroxypyrene at the OEL concentration. The end-of-shift concentration of 1-hydroxypyrene of 2.3 µmol mol Ϫ1 creatinine is proposed as the third level of the benchmark guideline, valid solely for cokeovens.
In workers from the primary aluminium industry the lowest reported concentration of 1-hydroxypyrene in urine at the end of a shift, which is equal to the TLV of 0.2 mg m Ϫ3 as BSM, is 4.9 µmol mol Ϫ1 creatinine. The relative proportion of pyrene in the PAH mixture of different worksites (paste plant, bakeoven and potrooms) in primary aluminium production varies widely. This may be the reason for the highly deviating levels of urinary 1-hydroxypyrene at the OEL exposure level. The lowest reported concentration of 1-hydroxypyrene, namely 4.9 µmol mol Ϫ1 creatinine is proposed as the third level of the benchmark guideline, and is valid solely for primary aluminium production. The benchmark proposal for primary aluminium workers fits quite nicely with the proposal that was recently published by Bouchard and Viau (1999) based on ratios between pyrene and benzo(a)pyrene equivalents. Urinary 1-hydroxypyrene as PAH biomarker Knowing that the US TLV of coal tar pitch volatiles (CTPV) as benzene soluble matter (BSM) has not been based on clear health risk levels from epidemiological studies, but rather on analytical demands (detectable concentration of benzene soluble matter), it should be clear that the TLV of CTPV is not a limit value, solely based on health risks, but is more or less a practical compromise (ACGIH, 1998) . Also the German TRK (Technische Richt Koncentration, that is Technical Guide Concentration) is based on the ALARA principle (as low as reasonably achievable). In The Netherlands, a health-based calculated OEL has recently been calculated for airborne benzo(a)pyrene using the linear extrapolation model to zero dose from tumour incidences at the risk level of 1:10 000 excess cancers per year for lifetime exposure-the estimate for the health-based calculated OEL was 0.315 µg m Ϫ3 benzo(a)pyrene (Netherlands Health Counsel, 1994) . It is clear that this estimate is far below the existing US TLV or German TRK. One should therefore realize that the third level of the benchmark guideline of urinary 1-hydroxypyrene is above a certain excess risk level. This conclusion is supported by data from studies of genotoxic effects in workers. These studies show lowest genotoxic effect levels in cokeoven workers at a concentration of 1-hydroxypyrene of 1.9 µmol mol Ϫ1 creatinine (increased level of single-strand breaks) and in the primary aluminium workers at 3.8 µmol mol Ϫ1 creatinine (increased level of PAH-DNA adducts). A complicating fact is that the results of the studies of PAH-DNA adducts in aluminium and electrode paste plant workers are not consistent (Cartensen et al., 1999) . Among four studies, only one study reported a dose-related increase in DNA adducts (van Schooten et al., 1995) .
In a number of studies the level of 1-hydroxypyrene in workers who smoke and are exposed to PAH is higher than the level in non-smoking colleagues; this indicated the need for a separate first level of the benchmark guideline for smokers and non-smokers. The second and third levels of the benchmark guideline, however, cannot be set for smokers and nonsmokers separately, since the majority of the present available studies of biological monitoring of exposure and monitoring of genotoxic effects among PAHexposed workers are not reported for these two groups, split by smoking habits.
No other international governmental organization has proposed a biological exposure limit yet. Lauwerys (1997) proposed in the chapter 'Occupational Toxicology' of the 5th edition of Cassett and Doull's Toxicology a tentative urinary 1-hydroxypyrene limit value of 2.7 µg g Ϫ1 (equal to 1.4 µmol mol Ϫ1 ). Several enzymes like the cytochrome P-450 1A1 and the glutathion transferases may mediate the metabolism of pyrene. The capacity of cytochrome P-450 1A1 may vary between individuals and interindividual differences exist. The meaning of the genetic polymorphism of cytochrome P450 1A1 and glutathione transferases to modulate the relationship of individual exposure to pyrene to individual urinary 1-hydroxypyrene concentrations is still too limited to introduce this as a clear modulating factor (Ovrebo et al., 1998; Wu et al., 1998b; Pan et al., 1998) .
Only when results from epidemiological studies of workers with long-term exposure to PAH, with urinary 1-hydroxypyrene as a dose indicator, will a more reliable estimate of the average 1-hydroxypyrene level versus excess tumour incidence be made. Only with these data will an accurate and precise estimate of the health-based limit value of urinary 1-hydroxypyrene be made. A guideline based on epidemiological data for exposed workers will be superior to the threelevel benchmark guideline presented here and such a standard will supersede the curent proposal when such studies are available.
